Development of a prediction model for 30-day COVID-19 hospitalization and death in a national cohort of Veterans Health Administration patients–March 2022—April 2023
Bui D, Bajema K, Huang Y, Yan L, Li Y, Rajeevan N, Berry K, Rowneki M, Argraves S, Hynes D, Huang G, Aslan M, Ioannou G. Development of a prediction model for 30-day COVID-19 hospitalization and death in a national cohort of Veterans Health Administration patients–March 2022—April 2023. PLOS ONE 2024, 19: e0307235. PMID: 39365775, PMCID: PMC11451987, DOI: 10.1371/journal.pone.0307235.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCOVID-19 hospitalizationArea under the receiver operating characteristic curveComprehensive electronic health recordNational cohortElectronic health recordsAll-cause mortalityNational cohort of patientsFull modelHealth recordsHealth AdministrationReceipt of COVID-19 vaccineMortality riskEpidemiology of COVID-19COVID-19High-risk patientsBrier scoreCohort of patientsAnti-SARS-CoV-2 treatmentCOVID-19 vaccineReceiver operating characteristic curveCalibration interceptHospitalAntiviral treatmentAvailability of effective vaccinesIdentifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Yan L, Bui D, Li Y, Rajeevan N, Rowneki M, Berry K, Argraves S, Huang Y, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation. Clinical Infectious Diseases 2024, 79: 643-651. PMID: 38864601, DOI: 10.1093/cid/ciae202.Peer-Reviewed Original ResearchRisk quartileVeterans Health AdministrationLowest risk quartileHighest risk quartileTarget trial emulationRisk prediction modelUntreated veteransRisk of deathOlder veteransYounger veteransHealth AdministrationTrial emulationMeasure incidenceNirmatrelvir-ritonavirVeteransHospitalUntreated participantsCOVID-19QuartileRiskSevere coronavirus disease 2019ParticipantsPersonsCoronavirus disease 2019Severe COVID-19